Form 8-K - Current report:
SEC Accession No. 0000950170-22-012322
Filing Date
2022-06-29
Accepted
2022-06-29 16:01:08
Documents
12
Period of Report
2022-06-24
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K ikt-20220624.htm   iXBRL 8-K 121721
  Complete submission text file 0000950170-22-012322.txt   251167

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ikt-20220624.xsd EX-101.SCH 2477
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ikt-20220624_lab.xml EX-101.LAB 18519
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ikt-20220624_pre.xml EX-101.PRE 11505
6 EXTRACTED XBRL INSTANCE DOCUMENT ikt-20220624_htm.xml XML 4886
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39676 | Film No.: 221054664
SIC: 2836 Biological Products, (No Diagnostic Substances)